Trial Profile
A phase 4, open label, randomized, controlled study to assess the effect on lipid profile of switching from a stable HAART regimen of fixed dose abacavir/lamivudine (Kivexa) plus efavirenz, to once daily Atripla in adult HIV-1 infected subjects with raised cholesterol.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms ROCKET-I
- Sponsors Gilead Sciences
- 15 Sep 2010 Results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
- 30 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 30 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.